根据Arcview的数据，Arcview说，Cure Pharmaceutical是一家领先的破坏性药物输送技术公司，研究和开发各种医疗保健应用的药物和大麻素分子，今天宣布其正式进入药品大麻行业的正式入口，据估计，到2020年，美国估计将超过230亿美元市场调查。
治愈了医药大麻素division to research and develop clinically ready cannabinoid drug formulations and delivery systems for both human and/or animal patients and is developing a global footprint with partners in the U.S., Canada, Israel and Germany, among other markets. The Company has taken a leadership role in optimizing plant base cannabinoids by vertically integrating drug discovery, proprietary extraction technology, genetic-specific cannabinoids research, and drug development.
“We are well-positioned in the pharmaceutical cannabis sector and excited to work within an industry with such a promising future,” said Rob Davidson, CEO of CURE. “Our goal is to bring new cannabinoid molecules to the market through the FDA regulatory process, while utilizing our company’s proprietary delivery technologies to increase efficacy, as well as target unmet needs in traditional pharmaceutical markets that could be disrupted by cannabinoid-based options.”
CURE正在研究和开发将不同大麻素和萜烯概况的专有配方集成到其先进的口服薄膜，Curefilm™和透皮应用中，利用其专有聚合物和封装技术。该公司致力于整合其专有的递送系统，以提供诸如疼痛，神经病，癌症（包括儿科癌症），PTSD和其他精神病，自身免疫性疾病，帕金森氏病和睡眠障碍等疾病的解决方案。
The Company is already actively forming several cannabinoid drug molecule partnerships and collaborations with some top healthcare and cannabis industry organizations globally. CURE is dedicated to providing knowledgeable updates on all of these partnerships and the innovative work they will be conducting.
For more information, click这里
